Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    • News

  • Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    • News

  • EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    • News

  • RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    • News

  • BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    • News

  • AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    • News

  • Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    • News

  • Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    • News

  • FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    • News

  • Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    • News

Why this human dermatology company is now looking into treatments for dogs

  • In News
  • September 29, 2021
  • Samantha Freidin
Why this human dermatology company is now looking into treatments for dogs

Pets are family. The staffy cross under my desk who lives here rent free will attest to that.

Our fur children are exactly that, children. With little personalities, quirks, likes and dislikes it’s hard not to think of the four legged friend you share your space with as more than a dog. 

Numerous studies have confirmed what us paw-rents already know, that pets lower stress levels and are good for human health. Pet owners in Germany and Australia visit their doctor 15% less annually than psychos  non-pet owners.

For (human) children, growing up with a pet in the house increases empathy and self-esteem levels and are less likely to develop allergies and asthma. 

Our love for our animals is reflected in the money we spend on them. My dog enjoys premium quality food ($70 per bag), a snuggly anti-anxiety bed ($150) and an array of enrichment toys and soft teddy bears to carry around the house ($$$$). When sick or uncomfortable, there’s little pet owners wouldn’t do, or spend, to restore their baby to health. 

With this knowledge, clinical stage dermatology company Botanix (ASX: BOT) has launched their canine atopic dermatitis program. The dermatology specialists note that atopic dermatitis in humans and dogs is immunologically very similar. Their proprietary drug is BTX 1204A, a topical formula containing CBD for its unique anti-inflammatory and immune modulating properties. 

The BTX 1204A canine study is now underway after receiving ethics approval. The study will look at 45 dogs across 3 sites in both Australia and New Zealand to evaluate the performance of two formulations of BTX 1204A for 28 days. 

Evidence from previous studies suggests that BTX 1204A could hold potential benefits to dogs suffering from dermatitis. Synthetic CBD can inhibit itch and repair the skin barrier as well as being an effective antimicrobial against staph infection causing bacteria. 

As well as opening up licensing opportunities within the animal health sector, findings from Botanix’s canine study could translate to ongoing human studies and support the progression to a Phase 2b clinical trial in humans. 

There is a large unmet need for an effective treatment for dermatitis which affects 31 million people in the US alone with 1 in 10 people set to develop symptoms at some point in their lifetime. Our four legged friends suffer too with many breeds being susceptible to dermatological issues. 

President and Executive Chairman of Botanix, Vince Ippolito said: “Following encouraging results of our pilot study in Q2 CY2021, we are excited to now commence a larger BTX1204A study in canines with atopic dermatitis. Given the similarity in disease between humans and canines, this study is an efficient and effective pathway to establishing the potential for a higher dose Permetrex formulation to demonstrate a new option for treating this significant disease challenge.” 

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  •  
  •  
  •  
  •  
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.